What 2018 Farm Bill Has In Store For The Hemp Industry?

On 20th December 2018, President Trump signed the 2018 Farm Bill. But it isn’t like any other farm bill. Apart from certain amendments in the agricultural and nutritional policies, it involves interesting changes for the hemp usage and consumption. Usually, cannabis is never a part of the conversation around crop insurance, nutritional assistance and farm subsidies. Yet, thanks to the constant support and leadership of Senate Majority Leader Mitch McConnell, the hemp issue has gained attention. According to the 2018 Farm Bill, hemp, a herb closely identical to marijuana and contains CBD (a highly touted wellness ingredient), is legalized.

Also,

  • Finally, after 50 years, hemp is considered as an agricultural product for the first time
  • According to some experts, the legalization may shed some light on the uses of CBD, which is an active ingredient of the first federally approved cannabis-based medicine in the United States
  • Even though cannabis is still considered federally illegal, the cannabis industry accounts for roughly $1 billion every year

This new and improved Farm Law is more extensive and allows the cultivation of hemp broadly, not merely pilot programs that enable marketers to study market interest in products derived from hemp. Now hemp-derived products are also allowed to be transferred across state borders for commercial purposes. Moreover, there is also no restrictions on the possession, transport, or sale of such products, provided those products are in compliance with the federal law.

Even though the new law has made many amendments in the previous Farm Law, it still has many restrictions.

The serious restrictions that come with Hemp legalization include:

THC content cannot be more than than 0.3%

As per the Farm Bill section 10113, hemp cannot contain over 0.3% THC. Any cannabis plant containing more than 0.3% THC will be considered a non-hemp marijuana or cannabis under

State-federal regulation on the cultivation of the crop

Even though hemp has been legalized by the federal government, hemp cultivation and production will still be regulated by both state and federal governments. As per the Farm Bill section 10113, state dfederal law and thus, would not be protected legally under the new Farm Bill. epartments of agriculture need to work in collaboration with the chief law enforcement officer and state’s governor to formulate a plan that should be presented to the secretary of the USDA. And only after taking an approval from the secretary of the USDA, a state’s plan for hemp regulation and licensing can be commenced. In states that choose not to formulate a hemp regulatory program, USDA will come into the picture and formulate the program. And this regulatory program will require cultivators to not only get a license for cultivation but also work in compliance with federally-run program.

Possible punishments for federal hemp law violations

The Farm Bill also includes various actions that are considered hemp law violations including activities such as producing hemp with more than 0.3% THC content or cultivating hemp without a license. The new Farm Law also outlines possible punishments for violators, pathways to comply with the law, and even actions which qualify as felonies as per the law, for an instance repeated offenses.

Hemp will be a highly regulated crop

The federal law has legalized the use of hemp, but it still can’t be cultivated as any other crop. As hemp has high potential for abuse, it will be a highly regulated crop for both industrial as well as personal production.

The legalization of hemp has brought a lot of hopes and opportunities for hemp industry. And according to Derek Riedle, publisher of Civilized, hemp is a versatile herb, and just because it is closely related to marijuana, it has earned a bad reputation. For decades, the government has failed to recognize the difference between the two and thus, couldn’t legalize the use of hemp. But now as the benefits of cannabis are unleashing, the federal government is making the necessary amendments to various laws.

CBD: Stanford University Scientists Launch Medical Marijuana Pharma Co For Manufacturing Drugs For Treating Incurable Neurodegenerative & Inflammatory Diseases

Stanford University scientists, Dr. Jonathan Rothbard, and Professor Lawrence Steinman have launched Katexco Pharmaceuticals, a medical marijuana company. According to the media reports, the newly launched Katexco Pharmaceuticals will produce CBD-based drugs that would exploit endocannabinoid and nicotine receptors in the brain for treating several neurodegenerative & inflammatory diseases where conventional medicines have failed.

Cannabis-based these drugs will exploit the key receptor CB2 on immune cells in the brain. The drugs would be useful for treating several diseases relating to inflammation of neurons and different regions of the brain that cause neurodegenerative diseases where current prescription drugs don’t show a good response.

One of the most important causes of severe and chronic neurodegenerative diseases is the decay of neurons, mainly due to inflammation. Immune responses are critical to neuron regeneration. Because there is no growth of new neurons, this results in the occurrence of the neurodegenerative conditions.

Besides certain cancers & HIV/ AIDS which are life-threatening diseases, also exists a group of neurodegenerative disorders that come up by aging, but it’s almost impossible to rid of them. Parkinson’s, Alzheimer’s and Huntington’s disease are just a few to name among the Dementia conditions, that affect most of the aged people and cripple their lives. As of now, there is no known conventional medicine that can cure these crippling illnesses.

The progression & dysfunction in all these conditions are slow. These conditions continue to deteriorate, but the symptoms are not visible on the early stage. And when the patient decides to consult a physician, it’s too late. By that time, about 80% of neurons & axons are already decayed, and there is no coming back.

What’s  Dementia – Alzheimer’s

You must have seen numerous patients battling with certain diseases with the hope that sooner or later, they might recover and come back to normal life.  But, on the back of the scene, they might not be aware of this hard fact that there is no medicines that might take them out of the nightmare they have entered due to wear & tear of neurons over years.

What’s Dementia - Alzheimer’s

Neurodegenerative disorders fall under the umbrella of conditions that come up due to inflammation, damage or death of neurons. Neurons are formed in the brain and Central Nervous System. When they get damaged, it’s not possible to repair them with conventional medicines that are available at present.

Most Common Neurodegenerative Disorders:

These include MS,  Parkinson’s, Alzheimer’s, Prion disease, Huntington’s disease (HD) malignant brain tumors,  Spinocerebellar ataxia, epilepsy related seizures. MND (Motor Neurone Diseases) Spinal muscular atrophy (SMA) and Neuralgia or neuropathic pain.

 When it’s about Alzheimer’s disease, the patients even do not know to whom they are interacting, what they are talking about and what’s happening. They might be freighted of things that don’t exist at all or they may feel talking to a person whom they have never seen.

In most of the cases, patients fail to know what’s happening with them. They are neither able to cater to their personal needs, nor can they discuss with their caretakers as what they need.

Neurological Effects of Medical Marijuana:

CBD, one of the main compounds of cannabis, protects the neurons from degeneration. A paper on the neurological benefits of phytocannabinoids, published by the NCBI in PMC, US National Library of Medicine, National Institutes of Health, (V-9/2018) supports this property of medical marijuana.

Anticonvulsant benefits of medical marijuana were first seen in the year 1980. Since then, cannabis has been tried for  various neurological uses. In the clinical and lab researches,   activation of the ECS has shown potential benefits in treating various critical conditions.

Cannabinoid receptors, CB (1) and CB (2), both bind to G proteins. CB (1) receptors. These receptors are found in central and peripheral neurons, On the other hand, CB (2) receptors are found on immune cells. This way, CB1 receptors mainly relate to the diseases of the CNS and CB2 receptors relate to our immune system.

At present, CB (1) & CB (2) agonists are potentially explored for therapeutic uses of cannabinoid receptor agonists for the management of inflammatory disorders, cancers and cancers related severe pains, MS, glaucoma, bronchial asthma, inflammatory pain and in the spasticity and schizophrenia.

Conclusion:

FDA has already approved CBD based drug Epidiolex manufactured by the GW Pharmaceuticals, for treating childhood related 2 types of childhood seizure disorders, Lennox-Gastaut and Dravet syndromes, entry of Katexco Pharmaceuticals in the medical marijuana industry would pave the way for replacing some of the prescription medicines, including opioids with the cannabis-based alternative medicines.

 

Benefits of different CBD:THC ratios in Medical Cannabis Strains

While visiting a medical cannabis dispensary, you might have noticed that different kinds of cannabis products are organized by Indica or Sativa content profile, and THC:CBD content.

However, either you ignore to ask or have no knowledge regarding these THC:CBD ratios.

Medical Cannabis is such an amazing plant where cannabinoids and terpenes work synergistically, and this collectively makes them full-spectrum extracts.

While THC has euphoric effects, CBD and terpenes are known for their non-psychoactive effects. Hence, the impact of a particular cannabis strain can vary dramatically depending upon the ratio of these two active cannabinoids.

Therefore, while purchasing medical cannabis in Orange County instead of just focussing on the dosage of cannabis, one should also have correct information about a variety of CBD:THC ratios.

Through this article, we will learn about the difference between these two cannabinoids and how their different ratios can help manage different conditions effectively.

CBD vs. THC

Marijuana contains over 100 types of active chemical compounds called cannabinoids.

Out of these cannabinoids, CBD and THC have been studied the most for their interaction with our body’s endocannabinoid system receptors.

They both possess different medicinal properties as well as effects on our body. This difference lies in the way they interact with the receptors in our body.

While THC binds CB1 receptor favorably, CBD acts as an antagonist to these receptors, sometimes partially blocking these CB1 receptors, thereby reducing euphoric effects of the THC molecule.

Properties of Cannabinoids:

THC is known for its euphoria while acting as an anti-inflammatory, anti-emetic, and an analgesic.

However, CBD shares some of these properties and is also known for its anti-seizure, anti-anxiety and antipsychotic properties.

Some studies even have reported that CBD is thought to enhance anti-cancer and pain reducing properties of cannabis.

Therefore, it is highly possible, depending on your particular condition, you will respond in a certain way to different CBD:THC ratios present in medical cannabis strains.

CBD:THC ratios and their benefits:

  • CBD:THC 0:1

This is a THC dominant strain where a  person will experience intense psychoactive effects.

Medical Cannabis strains with such ratios are known for uplifting  moods, thus making a person happy.

These strains can help induce appetite, reduce inflammation with relaxing effects.  

Examples- Gorilla Glue by Zamnesia with THC content of about 25%, and Girl Scout Cookies is loaded with around 22% of THC.

  • CBD:THC 1:2

This type of strain produces a calming sensation with reduced cases of anxiety.

Therefore, these strains can significantly reduce the euphoric effects of THC along with managing a number of conditions like chronic pain, anxiety, stress, insomnia, migraines, and muscle spasms.

Examples- Blue Widow, OG Kush.

  • CBD:THC 1:1

Research supports that strains with this kind of chemical makeup can be helpful in managing a number of chronic disorders.

This is because such strains can be used by any patient without bothering about the euphoric effects of THC.

Medical conditions and their associated symptoms which can be managed using this CBD:THC ratio are insomnia, fibromyalgia, autism, chronic pain, spasticity, reduced appetite, and skin diseases.  

Examples- Cannatonic, Sweet Tooth Auto, Critical Mass CBD.

  • CBD:THC 2:1 or 3:1

This particular ratio is ideal for many patients who wish to avoid the euphoric effects of THC.

It is suitable to combat autoimmune disorders, gastrointestinal issues like Crohn’s and colitis, arthritis, and psoriasis.

This type of medical cannabis strains are known for their calming effects.

Examples-Kama Kush CBD, CBD Critical Cure, and Cheese Autoflowering.

  • CBD:THC 1:0

Although this ratio is very rare in reality.

However, certain strains which are close to this ratio are CBD Therapy with 10% CBD and just 0.5% THC, Candida (CD-1) with 20%  CBD and only 1% THC.

This data will help you understand which medical cannabis strain will be helpful for your particular medical condition.

However, it is advised usually to start with a small dose of CBD rich ratio and then gradually add the THC content to get maximum therapeutic benefits.

In order to use this amazing plant for your health condition, I recommend one must always consult a medical cannabis specialist in Orange County, rather than indulging in any self-medication procedures.

Do share your personal experiences of particular medical marijuana strains and help us learn more about this amazing plant.